why would the stock move yet? It has limited potential for 2008, projected 8million in sales, 2009, projected 25million. Adolor recieved milestones payments from glaxo but has 50% revenue share agreement with glaxo. No appreciable dent in profits until fda approves other indications for drug. Doubt stock will move unless adolor earnings exceed projections. Label is very tight and so this will be unlikely. If sales projections are exceeded glaxo will likely buy company. 1-2 years out before you see return here. 2 pain products with pfizer not anywhere near approval.
just because hospitals are registering doesnt meant they are using it. heard its having a hard time getting added to the hospital formulary
Can anyone post info more useful than "bail, bail, bail?" I heard 20% of the registered hospitals had added to formulary and that this is a major push for the company. Does anyone know if this is accurate? Inaccurate? Progress thus far? And where is the info about GSK bailing out coming from? I would like to read it.
sales are awful; marketing didn't expect problems with P&T and will not admit they screwed up the projections. They are looking at $44.5 million in sales for anyone to get bonused.
